US00773U2078 - Common Stock
ADVERUM BIOTECHNOLOGIES INC
NASDAQ:ADVM (4/29/2024, 7:00:00 PM)
After market: 9.53 0 (0%)9.53
+0.34 (+3.7%)
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 123 full-time employees. The company went IPO on 2014-07-31. The firm discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein for ocular diseases. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
ADVERUM BIOTECHNOLOGIES INC
100 Cardinal Way
Redwood City CALIFORNIA 94063
P: 16506491004
CEO: Laurent Fischer
Employees: 123
Website: https://adverum.com/
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of...
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adverum Biotechnologies (NASDAQ:ADVM) just reported results for the fourth quar...
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety...
There are plenty of penny stocks ready to pop but we have to remember that penny stocks are extremely risky, too.
Here you can normally see the latest stock twits on ADVM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: